PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (NASDAQ: PTCT) announced the approval of equity compensation awards for 48 new employees. The company granted 19,475 non-statutory stock options at an exercise price of $58.99 per share and 39,060 restricted stock units (RSUs).
The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year and 6.25% quarterly thereafter. The RSUs also vest over four years, with 25% vesting annually. These inducement grants were approved by PTC's Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as part of new hire compensation packages.
PTC Therapeutics (NASDAQ: PTCT) ha annunciato l’approvazione di premi di compensazione azionaria per 48 nuovi dipendenti. L’azienda ha concesso 19.475 stock option non statutarie a un prezzo di esercizio di $58,99 per azione e 39.060 unità azionarie vincolate (RSU).
Le stock option hanno una durata di 10 anni con un periodo di vesting di 4 anni: il 25% si matura dopo un anno e il 6,25% trimestralmente dopo di che. Anche le RSU maturano su quattro anni, con il 25% di vesting annuo. Queste concessioni di incentivo sono state approvate dal Compensation Committee di PTC ai sensi della Nasdaq Listing Rule 5635(c)(4) come parte dei pacchetti di compensazione per i nuovi assunti.
PTC Therapeutics (NASDAQ: PTCT) anunció la aprobación de incentivos de compensación en acciones para 48 nuevos empleados. La compañía otorgó 19.475 opciones de acciones no estatutarias a un precio de ejercicio de $58.99 por acción y 39.060 unidades de acciones restringidas (RSU).
Las opciones tienen un plazo de 10 años con un cronograma de adquisición de 4 años: se adquiere el 25% después de un año y el 6.25% trimestralmente a partir de entonces. Las RSU también se acogen a un vesting de cuatro años, con un 25% de adquisición anual. Estas concesiones de inducción fueron aprobadas por el Comité de Compensación de PTC bajo la Nasdaq Listing Rule 5635(c)(4) como parte de los paquetes de compensación para nuevos empleados.
PTC Therapeutics(NASDAQ: PTCT)는 48명의 신규 직원에 대한 주식 보상 수여를 승인했다고 발표했습니다. 회사는 비공정 주식매수선택권 19,475주를 행사 가격 $58.99에, 그리고 제한 주식 단위(RSU) 39,060주를 부여했습니다.
주식매수선택권의 기간은 10년이며 4년 간의 vesting 일정이 있습니다: 1년 후 25%, 이후 매 분기 6.25%가 vesting됩니다. RSU 역시 4년 동안 vesting되며 매년 25%가 vest됩니다. 이 유인 부여는 신규 채용 보상 패키지의 일환으로 나스닥 상장 규정 5635(c)(4)에 따라 PTC의 보상위원회가 승인했습니다.
PTC Therapeutics (NASDAQ: PTCT) a annoncé l’approbation de primes de rémunération en actions pour 48 nouveaux employés. L’entreprise a accordé 19 475 options d’achat d’actions non statutaires à un prix d’exercice de $58,99 par action et 39 060 unités d’actions restreintes (RSU).
Les options d’achat d’actions ont une durée de 10 ans avec un calendrier d’acquisition sur 4 ans : 25% acquises après un an et 6,25% par trimestre par la suite. Les RSU se consolidant également sur quatre années, avec 25% d’acquisition annuelle. Ces attributions d’incitation ont été approuvées par le Comité de rémunération de PTC selon la Nasdaq Listing Rule 5635(c)(4) dans le cadre des packages de rémunération pour les nouveaux employés.
PTC Therapeutics (NASDAQ: PTCT) gab die Genehmigung von Aktienvergütungen für 48 neue Mitarbeiter bekannt. Das Unternehmen gewährt 19.475 nicht-statutäre Aktienoptionen zu einem Ausübungspreis von $58,99 pro Aktie und 39.060 Restricted Stock Units (RSUs).
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem Vesting-Plan über 4 Jahre: 25% vesten nach einem Jahr und danach 6,25% vierteljährlich. Die RSUs vesten ebenfalls über vier Jahre, mit 25% jährlich. Diese Einstiegszuwendungen wurden vom Vergütungsausschuss von PTC gemäß Nasdaq Listing Rule 5635(c)(4) genehmigt und sind Teil von Vergütungsplänen für neue Mitarbeiter.
PTC Therapeutics (NASDAQ: PTCT) أعلنت عن موافقة منح تعويض بالأسهم لـ 48 موظفًا جديدًا. منحت الشركة 19,475 خيار أسهم غير ساري بسعر تنفيذ $58.99 للسهم و 39,060 وحدات أسهم مقيدة (RSUs).
تمتلك خيارات الأسهم مدة عشر سنوات مع جدول ت περισ vesting على مدى أربعة أعوام: 25% تنمو بعد عام واحد و6.25% ربع سنويًا فيما بعد. كما vest RSUs على مدى أربع سنوات، مع vesting سنوي قدره 25%. تمت الموافقة على منح الحوافز هذه من قبل لجنة التعويض الخاصة بـ PTCT وفقًا لقواعد Nasdaq Listing Rule 5635(c)(4) كجزء من حزم تعويض للموظفين الجدد.
PTC Therapeutics（纳斯达克股票代码 PTCT）宣布批准为48名新员工授予股权激励。公司授予 19,475份非法定股票期权，行使价为 $58.99/股，以及 39,060份受限制股票单位（RSU）。
股票期权期限为 10年，4年 vesting 计划：在第一年结束时解锁 25%，此后每季度解锁 6.25%。RSU 同样在四年内解锁，年度解锁比例为 25%。这些引致性授予经由 PTC 的薪酬委员会根据 Nasdaq Listing Rule 5635(c)(4) 批准，作为新员工薪酬方案的一部分。
- None.
- None.
The inducement grants were approved by PTC's Compensation Committee on Sept. 28, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.
For more information, please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302572887.html
SOURCE PTC Therapeutics, Inc.
FAQ
What equity compensation did PTC Therapeutics (PTCT) grant to new employees in September 2025?
What is the vesting schedule for PTCT's September 2025 stock option grants?
How do the RSUs vest in PTC Therapeutics' September 2025 inducement grants?
What was the exercise price for PTC Therapeutics' September 2025 stock option grants?
